Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Apr;56(4):405-411.
doi: 10.1007/s00592-018-1267-z. Epub 2018 Dec 11.

Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry

Laura T Dickens  1 , Lisa R Letourneau  2 , May Sanyoura  2 , Siri Atma W Greeley  2 , Louis H Philipson  2 , Rochelle N Naylor  2
Affiliations
Observational Study

Management and pregnancy outcomes of women with GCK-MODY enrolled in the US Monogenic Diabetes Registry

Laura T Dickens et al. Acta Diabetol. 2019 Apr.

Abstract

Aims: GCK-MODY is characterized by mild hyperglycemia. Treatment is not required outside of pregnancy. During pregnancy, insulin treatment is recommended if second trimester fetal ultrasound monitoring shows macrosomia, suggesting the fetus has not inherited the GCK gene. There are limited data about GCK-MODY management in pregnancy. The aim of this study was to examine clinical management and pregnancy outcomes amongst women with a known diagnosis of GCK-MODY.

Methods: In this observational, cross-sectional study, a survey was distributed via Redcap to women ≥ 18 years enrolled in the University of Chicago Monogenic Diabetes Registry (n = 94). All or part of the survey was completed by 54 women (128 pregnancies).

Results: There were 78 term births (61%), 15 pre-term births (12%), and 24 miscarriages (19%). Of the 39 pregnancies where insulin was given, 22 (56%) had occasional or frequent hypoglycemia including 9 with severe hypoglycemia. Average birth weight for full-term GCK-affected infants was significantly less in cases of maternal insulin treatment versus no treatment (2967 and 3725 g, p = 0.005). For GCK-unaffected infants, conclusions are limited by small sample size but large for gestational age (LGA) was common with maternal insulin treatment (56%) and no treatment (33%), p = 0.590.

Conclusions: The observed miscarriage rate was comparable to the background US population rate (15-20%). Patients treated with insulin experienced a 23% incidence of severe hypoglycemia and lower birth weights were observed in the insulin-treated, GCK-affected neonates. These data support published guidelines of no treatment if the fetus is suspected to have inherited GCK-MODY and highlight the importance of additional studies to determine optimal pregnancy management for GCK-MODY, particularly among unaffected fetuses.

Keywords: Glucokinase; MODY; Pregnancy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest All authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Birth weight percentiles by fetal genotype/maternal treatment
See this image and copyright information in PMC

References

    1. Fajans SS, Bell GI, Polonsky KS (2001) Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 345(13):971–980 - PubMed
    1. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT (2014) Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 311(3):279–286. 10.1001/jama.2013.283980 - DOI - PubMed
    1. Stride A, Shields B, Gill-Carey O et al. (2014) Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 57(1):54–56. 10.1007/s00125-013-3075-x - DOI - PMC - PubMed
    1. Chakera AJ, Steele AM, Gloyn AL et al. (2015) Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care 38(7):1383–1392. 10.2337/dc14-2769 - DOI - PubMed
    1. Spyer G, Hattersley AT, Sykes JE, Sturley RH, MacLeod KM (2001) Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am J Obstet Gynecol 185(1):240–241 - PubMed

Publication types

MeSH terms

Supplementary concepts